In a historic breakthrough for targeted protein degradation, Bristol Myers Squibb has secured the first FDA approval for a CELMoD therapy, with clearance of Zenbexus (iberdomide) as part of a ...
A federal appeals court has overturned (PDF) the 2024 dismissal of a lawsuit filed by Celgene shareholders that accuses Bristol Myers Squibb of slow-walking the approval of blood cancer drug Breyanzi ...
Having spent 14 years building out its capacity, Regeneron Genetics Center—the genomic research branch of the Tarrytown, New ...
With the European Union formally reversing its marketing authorization for the rare disease med Tavneos last week, regulators from the bloc are laying out their concerns about the data backing the ...
AstraZeneca’s newly approved, first-in-class hypertension drug Baxfendy does not clear the bar for effectiveness relative to its price, according to the Institute for Clinical and Economic Review ...
With its reserves depleted, a debt payment due in four weeks and its cash runway stretching only into next month, the ...
With all the fretting from the pharmaceutical industry about competition from China, patent protection losses, price reduction initiatives and other government measures with the potential to hit pr | ...
Pushing back on the concept that there can only be one victor among branded obesity drugmakers, Novo Nordisk CEO Mike Doustdar thinks that investors aren’t seeing the whole picture. | As the massive ...
Two and a half years into his tenure as Emergent BioSolutions CEO, Joseph Papa is executing another round of restructuring to ...
More than four years after its CAR-T star Carvykti’s initial FDA approval, Legend Biotech has reached a major milestone, posting its first profitable quarter. | Legend Biotech's interim CEO, Alan Bash ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results